Bortezomib action in multiple myeloma: microRNA-mediated synergy (and miR-27a/CDK5 driven sensitivity)?

Bortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitors

(2011) P. Neri et al.   BLOOD

RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5

(2011) Y. X. Zhu et al.   BLOOD

miR-17-92 cluster microRNAs confers tumorigenicity in multiple myeloma

(2011) Lijuan Chen et al.   CANCER LETTERS

Down-regulated miR-331-5p and miR-27a are associated with chemotherapy resistance and relapse in leukaemia

(2010) Dan-Dan Feng et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Cancer cell sensitivity to bortezomib is associated with survivin and p53 status but not cancer cell types

(2010) Xiang Linf et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Dent's disease

(2010) Olivier Devuyst et al.   Orphanet Journal of Rare Diseases

Bortezomib induces canonical nuclear factor- B activation in multiple myeloma cells

(2009) T. Hideshima et al.   BLOOD

Role of microRNA in anticancer drug resistance

(2009) Tongsen Zheng et al.   INTERNATIONAL JOURNAL OF CANCER

Redox homeostasis modulates the sensitivity of myeloma cells to bortezomib

(2008) Silvia Nerini-Molteni et al.   BRITISH JOURNAL OF HAEMATOLOGY

BAG3 gene silencing sensitizes leukemic cells to Bortezomib-induced apoptosis

(2008) Peng Liu et al.   FEBS LETTERS